{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:25:59Z","timestamp":1795029959046,"version":"4.10.2"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C3\/20\/090, C3\/21\/035, C24\/18\/101, IDN\/21\/013"],"award-info":[{"award-number":["C3\/20\/090, C3\/21\/035, C24\/18\/101, IDN\/21\/013"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC StG 750973"],"award-info":[{"award-number":["ERC StG 750973"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-024-02951-1","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T07:59:42Z","timestamp":1731225582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Silver nanoparticle induced immunogenic cell death can improve immunotherapy"],"prefix":"10.1186","volume":"22","author":[{"given":"Ara","family":"Sargsian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xanthippi","family":"Koutsoumpou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermon","family":"Girmatsion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Egil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiana","family":"Buttiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Rios","family":"Luci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefaan J.","family":"Soenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella B.","family":"Manshian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,10]]},"reference":[{"issue":"5","key":"2951_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.apsb.2015.07.005","volume":"5","author":"X Guan","year":"2015","unstructured":"Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5(5):402\u201318.","journal-title":"Acta Pharm Sin B"},{"key":"2951_CR2","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 2020 111 [Internet]. 2020 Jul 30 [cited 2021 Nov 28];11(1):1\u20133. https:\/\/www.nature.com\/articles\/s41467-020-17670-y"},{"key":"2951_CR3","doi-asserted-by":"crossref","unstructured":"Jia L, Zhang Q, Zhang R. PD-1\/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biol Med [Internet]. 2018 May 1 [cited 2021 Nov 28];15(2):116. https:\/\/www.pmc\/articles\/PMC5994550","DOI":"10.20892\/j.issn.2095-3941.2017.0086"},{"key":"2951_CR4","doi-asserted-by":"crossref","unstructured":"De Sousa Linhares A, Battin C, Jutz S, Leitner J, Hafner C, Tobias J et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\/PD-L1 signaling. Sci Reports 2019 91 [Internet]. 2019 Aug 7 [cited 2021 Nov 28];9(1):1\u20139. https:\/\/www.nature.com\/articles\/s41598-019-47910-1","DOI":"10.1038\/s41598-019-47910-1"},{"issue":"Pt 2","key":"2951_CR5","doi-asserted-by":"publisher","first-page":"127911","DOI":"10.1016\/j.ijbiomac.2023.127911","volume":"254","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Wang H, Li J, Jiang X, Li Z, Shen J. Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review. Int J Biol Macromol. 2024;254(Pt 2):127911.","journal-title":"Int J Biol Macromol"},{"key":"2951_CR6","doi-asserted-by":"publisher","unstructured":"Zhou Z, Chen J, Liu Y, Zheng C, Luo W, Chen L et al. Cascade two-stage tumor re-oxygenation and immune re-sensitization mediated by self-assembled albumin-sorafenib nanoparticles for enhanced photodynamic immunotherapy. Acta Pharm Sin B [Internet]. 2022;12(11):4204\u201323. https:\/\/doi.org\/10.1016\/j.apsb.2022.07.023","DOI":"10.1016\/j.apsb.2022.07.023"},{"issue":"3","key":"2951_CR7","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.18632\/oncotarget.23279","volume":"9","author":"G Huang","year":"2018","unstructured":"Huang G, Sun X, Liu D, Zhang Y, Zhang B, Xiao G, et al. The efficacy and safety of anti-PD-1\/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: A meta-analysis. Oncotarget. 2018;9(3):4239\u201348.","journal-title":"Oncotarget"},{"key":"2951_CR8","doi-asserted-by":"crossref","unstructured":"Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009 95 [Internet]. 2009 May [cited 2021 Dec 8];9(5):353\u201363. https:\/\/www.nature.com\/articles\/nri2545","DOI":"10.1038\/nri2545"},{"issue":"4","key":"2951_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.it.2011.01.005","volume":"32","author":"DV Krysko","year":"2011","unstructured":"Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol. 2011;32(4):157\u201364.","journal-title":"Trends Immunol"},{"key":"2951_CR10","doi-asserted-by":"crossref","unstructured":"Joshi S, Durden DL. Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. J Oncol [Internet]. 2019 [cited 2021 Nov 9];2019. https:\/\/www.pmc\/articles\/PMC6377965\/","DOI":"10.1155\/2019\/5245034"},{"key":"2951_CR11","doi-asserted-by":"crossref","unstructured":"Boone CE, Wang L, Gautam A, Newton IG, Steinmetz NF. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol [Internet]. 2021 [cited 2021 Nov 9]; https:\/\/pubmed.ncbi.nlm.nih.gov\/34296535\/","DOI":"10.1002\/wnan.1739"},{"issue":"11","key":"2951_CR12","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/nnano.2016.168","volume":"11","author":"S Zanganeh","year":"2016","unstructured":"Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat Nanotechnol. 2016;11(11):986\u201394.","journal-title":"Nat Nanotechnol"},{"issue":"46","key":"2951_CR13","doi-asserted-by":"publisher","first-page":"21985","DOI":"10.1039\/C8NR05220D","volume":"10","author":"J Burk","year":"2018","unstructured":"Burk J, Sikk L, Burk P, Manshian BB, Soenen SJ, Scott-Fordsmand JJ, et al. Fe-Doped ZnO nanoparticle toxicity: Assessment by a new generation of nanodescriptors. Nanoscale. 2018;10(46):21985\u201393.","journal-title":"Nanoscale"},{"issue":"42","key":"2951_CR14","doi-asserted-by":"publisher","first-page":"27981","DOI":"10.1039\/C5CP00831J","volume":"17","author":"K McNamara","year":"2015","unstructured":"McNamara K, Tofail SAM, Nanosystems. The use of nanoalloys, metallic, bimetallic, and magnetic nanoparticles in biomedical applications. Phys Chem Chem Phys. 2015;17(42):27981\u201395.","journal-title":"Phys Chem Chem Phys"},{"issue":"2","key":"2951_CR15","doi-asserted-by":"publisher","first-page":"e1629","DOI":"10.1038\/cddis.2014.576","volume":"6","author":"L Baron","year":"2015","unstructured":"Baron L, Gombault A, Fanny M, Villeret B, Savigny F, Guillou N, et al. The NLRP3 inflammasome is activated by nanoparticles through ATP, ADP and adenosine. Cell Death Dis. 2015;6(2):e1629.","journal-title":"Cell Death Dis"},{"issue":"9","key":"2951_CR16","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1039\/D0NA00286K","volume":"2","author":"C Maksoudian","year":"2020","unstructured":"Maksoudian C, Saffarzadeh N, Hesemans E, Dekoning N, Buttiens K, Soenen SJ. Role of inorganic nanoparticle degradation in cancer therapy. Nanoscale Adv. 2020;2(9):3734\u201363.","journal-title":"Nanoscale Adv"},{"key":"2951_CR17","doi-asserted-by":"crossref","unstructured":"Soenen SJ, Parak WJ, Rejman J, Manshian B. (Intra)Cellular Stability of Inorganic Nanoparticles: Effects on Cytotoxicity, Particle Functionality, and Biomedical Applications. 2015 [cited 2024 Jan 26]; https:\/\/pubs.acs.org\/sharingguidelines","DOI":"10.1021\/cr400714j"},{"issue":"14","key":"2951_CR18","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.2174\/1389450115666140804124808","volume":"16","author":"J Wolfram","year":"2015","unstructured":"Wolfram J, Zhu M, Yang Y, Shen J, Gentile E, Paolino D, et al. Safety of Nanoparticles in Medicine. Curr Drug Targets. 2015;16(14):1671\u201381.","journal-title":"Curr Drug Targets"},{"issue":"1","key":"2951_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12951-023-01844-z","volume":"21","author":"E Hesemans","year":"2023","unstructured":"Hesemans E, Saffarzadeh N, Maksoudian C, Izci M, Chu T, Rios Luci C, et al. Cu-doped TiO(2) nanoparticles improve local antitumor immune activation and optimize dendritic cell vaccine strategies. J Nanobiotechnol. 2023;21(1):87.","journal-title":"J Nanobiotechnol"},{"key":"2951_CR20","doi-asserted-by":"publisher","unstructured":"Manshian BB, Pokhrel S, Himmelreich U, T\u00e4mm K, Sikk L, Fern\u00e1ndez A et al. In Silico Design of Optimal Dissolution Kinetics of Fe-Doped ZnO Nanoparticles Results in Cancer-Specific Toxicity in a Preclinical Rodent Model. Adv Healthc Mater [Internet]. 2017;6(9):1601379. https:\/\/doi.org\/10.1002\/adhm.201601379","DOI":"10.1002\/adhm.201601379"},{"key":"2951_CR21","doi-asserted-by":"publisher","unstructured":"Naatz H, Manshian BB, Luci CR, Tsikourkitoudi V, Deligiannakis Y, Birkenstock J et al. Model-Based Nanoengineered Pharmacokinetics of Iron-Doped Copper Oxide for Nanomedical Applications. Angew Chemie [Internet]. 2020 Jan 27 [cited 2021 Nov 6];132(5):1844\u201352. https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1002\/ange.201912312","DOI":"10.1002\/ange.201912312"},{"issue":"12","key":"2951_CR22","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1016\/j.sjbs.2020.09.004","volume":"27","author":"L Oprica","year":"2020","unstructured":"Oprica L, Andries M, Sacarescu L, Popescu L, Pricop D, Creanga D, et al. Citrate-silver nanoparticles and their impact on some environmental beneficial fungi. Saudi J Biol Sci. 2020;27(12):3365\u201375.","journal-title":"Saudi J Biol Sci"},{"key":"2951_CR23","doi-asserted-by":"crossref","unstructured":"Zhang H, Wei X, Liu L, Zhang Q, Jiang W. The role of positively charged sites in the interaction between model cell membranes and \u03b3-Fe2O3 NPs. Sci Total Environ [Internet]. 2019;673:414\u201323. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0048969719315943","DOI":"10.1016\/j.scitotenv.2019.04.074"},{"key":"2951_CR24","doi-asserted-by":"crossref","unstructured":"R\u00f3nav\u00e1ri A, B\u00e9lteky P, Boka E, Zakupszky D, Igaz N, Szerencs\u00e9s B et al. Polyvinyl-Pyrrolidone-Coated Silver Nanoparticles-The Colloidal, Chemical, and Biological Consequences of Steric Stabilization under Biorelevant Conditions. Int J Mol Sci. 2021;22(16).","DOI":"10.3390\/ijms22168673"},{"key":"2951_CR25","doi-asserted-by":"crossref","unstructured":"Pinzaru I, Coricovac D, Dehelean C, Moac\u0103 E-A, Mioc M, Baderca F et al. Stable PEG-coated silver nanoparticles \u2013 A comprehensive toxicological profile. Food Chem Toxicol [Internet]. 2018;111:546\u201356. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0278691517307317","DOI":"10.1016\/j.fct.2017.11.051"},{"key":"2951_CR26","doi-asserted-by":"crossref","unstructured":"Stein R, Friedrich B, M\u00fchlberger M, Cebulla N, Schreiber E, Tietze R et al. Synthesis and Characterization of Citrate-Stabilized Gold-Coated Superparamagnetic Iron Oxide Nanoparticles for Biomedical Applications. Vol. 25, Molecules. 2020.","DOI":"10.3390\/molecules25194425"},{"key":"2951_CR27","doi-asserted-by":"crossref","unstructured":"McComiskey KPM, Tajber L. Comparison of particle size methodology and assessment of nanoparticle tracking analysis (NTA) as a tool for live monitoring of crystallisation pathways. Eur J Pharm Biopharm [Internet]. 2018;130:314\u201326. http:\/\/europepmc.org\/abstract\/MED\/30012404","DOI":"10.1016\/j.ejpb.2018.07.012"},{"issue":"5","key":"2951_CR28","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s11095-010-0073-2","volume":"27","author":"V Filipe","year":"2010","unstructured":"Filipe V, Hawe A, Jiskoot W. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res. 2010;27(5):796\u2013810.","journal-title":"Pharm Res"},{"key":"2951_CR29","doi-asserted-by":"crossref","unstructured":"Akter M, Sikder MT, Rahman MM, Ullah AKMA, Hossain KFB, Banik S, et al. A systematic review on silver nanoparticles-induced cytotoxicity: Physicochemical properties and perspectives. Journal of Advanced Research. Volume 9. Elsevier B.V.; 2018. pp. 1\u201316.","DOI":"10.1016\/j.jare.2017.10.008"},{"issue":"6","key":"2951_CR30","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.tiv.2013.07.005","volume":"27","author":"RY Prasad","year":"2013","unstructured":"Prasad RY, McGee JK, Killius MG, Suarez DA, Blackman CF, DeMarini DM, et al. Investigating oxidative stress and inflammatory responses elicited by silver nanoparticles using high-throughput reporter genes in HepG2 cells: Effect of size, surface coating, and intracellular uptake. Toxicol Vitr. 2013;27(6):2013\u201321.","journal-title":"Toxicol Vitr"},{"key":"2951_CR31","doi-asserted-by":"publisher","unstructured":"Kim JA, \u00c5berg C, Salvati A, Dawson KA. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat Nanotechnol [Internet]. 2012;7(1):62\u20138. https:\/\/doi.org\/10.1038\/nnano.2011.191","DOI":"10.1038\/nnano.2011.191"},{"key":"2951_CR32","doi-asserted-by":"publisher","unstructured":"Gliga AR, Skoglund S, Odnevall Wallinder I, Fadeel B, Karlsson HL. Size-dependent cytotoxicity of silver nanoparticles in human lung cells: The role of cellular uptake, agglomeration and Ag release. Part Fibre Toxicol [Internet]. 2014 Feb 17 [cited 2020 May 14];11(1):11. http:\/\/particleandfibretoxicology.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/1743-8977-11-11","DOI":"10.1186\/1743-8977-11-11"},{"issue":"3","key":"2951_CR33","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1073\/pnas.241655498","volume":"99","author":"M Ott","year":"2002","unstructured":"Ott M, Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S. Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci U S A. 2002;99(3):1259\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2951_CR34","doi-asserted-by":"publisher","first-page":"1601379","DOI":"10.1002\/adhm.201601379","volume":"6","author":"BB Manshian","year":"2017","unstructured":"Manshian BB, Pokhrel S, Himmelreich U, T\u00e4mm K, Sikk L, Fern\u00e1ndez A, et al. In Silico Design of Optimal Dissolution Kinetics of Fe-Doped ZnO Nanoparticles Results in Cancer-Specific Toxicity in a Preclinical Rodent Model. Adv Healthc Mater. 2017;6(9):1601379.","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"2951_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1021\/nn901503q","volume":"4","author":"S George","year":"2010","unstructured":"George S, Pokhrel S, Xia T, Gilbert B, Ji Z, Schowalter M, et al. Use of a rapid cytotoxicity screening approach to engineer a safer zinc oxide nanoparticle through iron doping. ACS Nano. 2010;4(1):15\u201329.","journal-title":"ACS Nano"},{"key":"2951_CR36","doi-asserted-by":"crossref","unstructured":"Garg AD, Dudek-Peric AM, Romano E, Agostinis P. Immunogenic cell death. Int J Dev Biol [Internet]. 2015 Sep 3 [cited 2020 Feb 29];59(1-2-3):131\u201340. http:\/\/www.intjdevbiol.com\/paper.php?doi=150061pa","DOI":"10.1387\/ijdb.150061pa"},{"key":"2951_CR37","doi-asserted-by":"crossref","unstructured":"Baeza A. Tumor Targeted Nanocarriers for Immunotherapy. Molecules. 2020;25(7).","DOI":"10.3390\/molecules25071508"},{"key":"2951_CR38","doi-asserted-by":"publisher","unstructured":"Chavdarov Chonov D, Magdalena Krasimirova Ignatova M, Rumenov Ananiev J, Vladova Gulubova M. IL-6 Activities in the Tumour Microenvironment. Part 1 the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Maced J Med Sci [Internet]. 2019 [cited 2023 Sep 8];7(14):2391. https:\/\/doi.org\/10.3889\/oamjms.2019.589","DOI":"10.3889\/oamjms.2019.589"},{"key":"2951_CR39","doi-asserted-by":"crossref","unstructured":"Wu C-T, Chen M-F, Chen W-C, Hsieh C-C. The role of IL-6 in the radiation response of prostate cancer. 2013 [cited 2023 Sep 11]; http:\/\/www.ro-journal.com\/content\/8\/1\/159","DOI":"10.1186\/1748-717X-8-159"},{"issue":"5","key":"2951_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/icb.2012.9","volume":"90","author":"NA De Weerd","year":"2012","unstructured":"De Weerd NA, Nguyen T. The interferons and their receptors-distribution and regulation. Immunol Cell Biol. 2012;90(5):483\u201391.","journal-title":"Immunol Cell Biol"},{"key":"2951_CR41","doi-asserted-by":"publisher","unstructured":"Cheon HJ, Wang Y, Wightman SM, Jackson MW, Stark GR. How cancer cells make and respond to interferon-I. Trends in Cancer [Internet]. 2023;9(1):83\u201392. https:\/\/doi.org\/10.1016\/j.trecan.2022.09.003","DOI":"10.1016\/j.trecan.2022.09.003"},{"key":"2951_CR42","doi-asserted-by":"crossref","unstructured":"Shi W, Yao X, Fu Y, Wang Y. Interferon-\u03b1 and its effects on cancer cell apoptosis (Review). Oncol Lett. 2022;24(1).","DOI":"10.3892\/ol.2022.13355"},{"issue":"May","key":"2951_CR43","first-page":"1","volume":"14","author":"J Han","year":"2023","unstructured":"Han J, Wu M, Liu Z. Dysregulation in IFN-\u03b3 signaling and response: the barricade to tumor immunotherapy. Front Immunol. 2023;14(May):1\u201312.","journal-title":"Front Immunol"},{"key":"2951_CR44","doi-asserted-by":"crossref","unstructured":"Bhat P, Leggatt G, Waterhouse N, Frazer IH. Interferon-\u03b3 derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis [Internet]. 2017 [cited 2023 Sep 12];8(6). https:\/\/pubmed.ncbi.nlm.nih.gov\/28569770\/","DOI":"10.1038\/cddis.2017.67"},{"key":"2951_CR45","doi-asserted-by":"crossref","unstructured":"Zaidi MR. The Interferon-Gamma Paradox in Cancer. J Interferon Cytokine Res [Internet]. 2019 Jan 1 [cited 2023 Sep 12];39(1):30\u20138. https:\/\/pubmed.ncbi.nlm.nih.gov\/30388040\/","DOI":"10.1089\/jir.2018.0087"},{"key":"2951_CR46","doi-asserted-by":"crossref","unstructured":"Singh S, Kumar S, Srivastava RK, Nandi A, Thacker G, Murali H et al. Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-\u03b3 signalling. Nat Cell Biol [Internet]. 2020 May 1 [cited 2023 Sep 12];22(5):591\u2013602. https:\/\/pubmed.ncbi.nlm.nih.gov\/32284542\/","DOI":"10.1038\/s41556-020-0495-y"},{"key":"2951_CR47","doi-asserted-by":"crossref","unstructured":"Mo X, Zhang H, Preston S, Martin K, Zhou B, Vadalia N et al. Interferon-\u03b3 Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4. Cancer Res [Internet]. 2018 Jan 15 [cited 2023 Sep 12];78(2):436\u201350. https:\/\/pubmed.ncbi.nlm.nih.gov\/29150430\/","DOI":"10.1158\/0008-5472.CAN-17-1615"},{"key":"2951_CR48","doi-asserted-by":"crossref","unstructured":"Williams CL, Schilling MM, Cho SH, Lee K, Wei M, Aditi et al. STAT4 and T-bet are required for the plasticity of IFN-\u03b3 expression across Th2 ontogeny and influence changes in Ifng promoter DNA methylation. J Immunol [Internet]. 2013 Jul 15 [cited 2023 Sep 12];191(2):678\u201387. https:\/\/pubmed.ncbi.nlm.nih.gov\/23761633\/","DOI":"10.4049\/jimmunol.1203360"},{"key":"2951_CR49","doi-asserted-by":"crossref","unstructured":"van Horssen R, ten Hagen TLM, Eggermont AMM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist [Internet]. 2006 Apr 1 [cited 2023 Sep 12];11(4):397\u2013408. https:\/\/pubmed.ncbi.nlm.nih.gov\/16614236\/","DOI":"10.1634\/theoncologist.11-4-397"},{"key":"2951_CR50","doi-asserted-by":"publisher","unstructured":"Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature [Internet]. 2012;490(7420):412\u20136. https:\/\/doi.org\/10.1038\/nature11538","DOI":"10.1038\/nature11538"},{"issue":"3","key":"2951_CR51","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1084\/jem.20110367","volume":"208","author":"E Naik","year":"2011","unstructured":"Naik E, Dixit VM. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J Exp Med. 2011;208(3):417\u201320.","journal-title":"J Exp Med"},{"key":"2951_CR52","doi-asserted-by":"crossref","unstructured":"Zhou J, Wang G, Chen Y, Wang H, Hua Y, Cai Z. Immunogenic cell death in cancer therapy: Present and emerging inducers. J Cell Mol Med [Internet]. 2019 Aug 1 [cited 2021 Oct 28];23(8):4854. https:\/\/www.pmc\/articles\/PMC6653385\/","DOI":"10.1111\/jcmm.14356"},{"key":"2951_CR53","doi-asserted-by":"crossref","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Frontiers in Oncology. Volume 8. Frontiers Media S.A.; 2018.","DOI":"10.3389\/fonc.2018.00086"},{"key":"2951_CR54","doi-asserted-by":"crossref","unstructured":"Golombek SK, May JN, Theek B, Appold L, Drude N, Kiessling F, et al. Tumor targeting via EPR: Strategies to enhance patient responses. Advanced Drug Delivery Reviews. Volume 130. Elsevier B.V.; 2018. pp. 17\u201338.","DOI":"10.1016\/j.addr.2018.07.007"},{"key":"2951_CR55","doi-asserted-by":"crossref","unstructured":"Suda K. Tumor-associated macrophages-additional effectors at anti-PD-1\/PD-L1 therapy? Journal of thoracic disease. Volume 9. China; 2017. pp. 4197\u2013200.","DOI":"10.21037\/jtd.2017.10.15"},{"key":"2951_CR56","doi-asserted-by":"crossref","unstructured":"Lerman I, De La Luz Garcia-Hernandez M, Rangel-Moreno J, Chiriboga L, Pan C, Nastiuk KL et al. Infiltrating Myeloid Cells Exert Pro-Tumorigenic Actions via Neutrophil Elastase. Mol Cancer Res [Internet]. 2017 Sep 1 [cited 2023 Feb 6];15(9):1138. https:\/\/www.pmc\/articles\/PMC5581693\/","DOI":"10.1158\/1541-7786.MCR-17-0003"},{"key":"2951_CR57","doi-asserted-by":"publisher","first-page":"925135","DOI":"10.1155\/2012\/925135","volume":"2012","author":"RV Luckheeram","year":"2012","unstructured":"Luckheeram RV, Zhou R, Verma AD, Xia B. CD4+T cells: differentiation and functions. Clin Dev Immunol. 2012;2012:925135.","journal-title":"Clin Dev Immunol"},{"key":"2951_CR58","doi-asserted-by":"publisher","unstructured":"Koh C-H, Lee S, Kwak M, Kim B-S, Chung Y. CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. Exp Mol Med [Internet]. 2023;55(11):2287\u201399. https:\/\/doi.org\/10.1038\/s12276-023-01105-x","DOI":"10.1038\/s12276-023-01105-x"},{"issue":"6","key":"2951_CR59","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/eji.201646837","volume":"47","author":"D Cibri\u00e1n","year":"2017","unstructured":"Cibri\u00e1n D, S\u00e1nchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 2017;47(6):946\u201353.","journal-title":"Eur J Immunol"},{"key":"2951_CR60","doi-asserted-by":"publisher","unstructured":"Sandoval-Montes C, Santos-Argumedo L. CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines. J Leukoc Biol [Internet]. 2005;77(4):513\u201321. https:\/\/doi.org\/10.1189\/jlb.0404262","DOI":"10.1189\/jlb.0404262"}],"updated-by":[{"DOI":"10.1186\/s12951-024-03081-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000}}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02951-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-024-02951-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02951-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T01:43:14Z","timestamp":1737078194000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-024-02951-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,10]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2951"],"URL":"https:\/\/doi.org\/10.1186\/s12951-024-02951-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.13.607617","asserted-by":"object"}]},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,10]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12951-024-03081-4","URL":"https:\/\/doi.org\/10.1186\/s12951-024-03081-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"691"}}